Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,420 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Active capsule Clear all

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: RGH-896, pregabalin, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 54
States / cities: Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 51 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: South Miami, Florida • Durham, North Carolina

Conditions: Clostridioides Difficile Infection
Interventions: CRS3123, Active Comparator; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Lancaster, California • Mission Hills, California + 14 more

Conditions: HIV Infections, Heart Disease
Interventions: Rosuvastatin 10 mg. daily for 96 weeks, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Kidney Disease, Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 34
States / cities: Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Covid-19
Interventions: Antroquinonol, Placebo; Drug · Other
Lead sponsor: Golden Biotechnology Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more

Conditions: Acute Pain
Interventions: Placebo, Naproxen, Pregabalin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis, Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more

Conditions: Uncomplicated Urinary Tract Infections
Interventions: Pivya (Pivmecillinam 185 mg), Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule); Drug
Lead sponsor: Alembic Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dearborn Heights, Michigan

Conditions: Venous Thromboembolism
Interventions: dabigatran etexilate, standard of care; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Up to 17 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Tampa, Florida + 6 more

Conditions: Sleep
Interventions: Placebo Capsule, POWEROFF Capsule; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Lenalidomide 25 MG Oral Capsule; Drug
Lead sponsor: Starton Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Wilson, North Carolina • Canton, Ohio

Conditions: Drug Abuse
Interventions: Istradefylline, Phentermine 45 mg, Placebo; Drug · Other
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension
Interventions: Darusentan, Guanfacine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more

Conditions: Cervical Dysplasia
Interventions: di indolylmethane (DIM), Red rice bran; Drug · Dietary Supplement
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Bariatric Surgery Candidate, Bone Loss, Weight Loss
Interventions: Risedronate Sodium 150 MG, Placebo; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psychedelic Experiences
Interventions: psilocybin trihydrate, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Conditions: Old Adults, Sleep Quality, Kava, Mobility Impairment, Physical Activity and Stress, Physical Impairment, Sedentary Lifestyle in Patients Over 70
Interventions: AB-free kava, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 70 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
Interventions: IMR-687, Placebo Oral Capsule; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HDL
Interventions: CardioLux™HDL, Placebo; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

Human Experimental Models of Pain (HEMP)

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

A Study to Investigate Pivmecillinam Versus Nitrofurantoin in Female Adolescents 12 to Less Than 18 Years of Age With Uncomplicated Urinary Tract Infection

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

The Poweroff Sleep Study

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

RCT of a Polyherbal Dietary Supplement for Prediabetes

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

A Study to Evaluate Abuse Potential of Istradefylline

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

Weight Loss With Risedronate for Bone Health

Safety for Home Administration of Microdose Psilocybin Use

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

Kava Aging and Mobility Study

A Study of IMR-687 in Healthy Adult Volunteers

Oral Nutritional Supplement Effect on HDL Function